These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 35412326)

  • 1. Population-level implications of the Israeli booster campaign to curtail COVID-19 resurgence.
    Gavish N; Yaari R; Huppert A; Katriel G
    Sci Transl Med; 2022 Jun; 14(647):eabn9836. PubMed ID: 35412326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
    Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Israeli health system's rapid responses during the COVID-19 pandemic.
    Rosen B; Hartal M; Waitzberg R
    Isr J Health Policy Res; 2024 Mar; 13(1):11. PubMed ID: 38438926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 Boosters: If The US Had Matched Israel's Speed And Take-Up, An Estimated 29,000 US Lives Would Have Been Saved.
    Black B; Atanasov V; Glatman-Freedman A; Keinan-Boker L; Reichman A; Franchi L; Meurer J; Luo Q; Thaw DB; Moghtaderi A
    Health Aff (Millwood); 2023 Dec; 42(12):1747-1757. PubMed ID: 38048511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A deep look into the storm: Israeli multi-center experience of coronavirus disease 2019 (COVID-19) in patients with autoimmune inflammatory rheumatic diseases before and after vaccinations.
    Kharouf F; Eviatar T; Braun M; Pokroy-Shapira E; Brodavka M; Zloof Y; Agmon-Levin N; Toledano K; Oren S; Lidar M; Zisman D; Tavor Y; Amit-Vazina M; Sabbah F; Breuer GS; Dagan A; Beshara-Garzuzi R; Markovits D; Elias M; Feld J; Tayer-Shifman O; Gazitt T; Reitblatt T; Rubin L; Haddad A; Giryes S; Paran D; Peleg H; Molad Y; Elkayam O; Mevorach D; Balbir-Gurman A; Braun-Moscovici Y
    Front Immunol; 2023; 14():1064839. PubMed ID: 36993961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling COVID-19 vaccine breakthrough infections in highly vaccinated Israel-The effects of waning immunity and third vaccination dose.
    Feng A; Obolski U; Stone L; He D
    PLOS Glob Public Health; 2022; 2(11):e0001211. PubMed ID: 36962648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the impact of Australia's mass vaccination campaigns over the Delta and Omicron outbreaks.
    Lin L; Demirhan H; P Johnstone-Robertson S; Lal R; M Trauer J; Stone L
    PLoS One; 2024; 19(4):e0299844. PubMed ID: 38626045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study.
    Zhou W; Tang B; Bai Y; Shao Y; Xiao Y; Tang S
    Vaccine; 2022 Nov; 40(49):7141-7150. PubMed ID: 36328883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.
    Levine-Tiefenbrun M; Yelin I; Alapi H; Katz R; Herzel E; Kuint J; Chodick G; Gazit S; Patalon T; Kishony R
    Nat Med; 2021 Dec; 27(12):2108-2110. PubMed ID: 34728830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel.
    Glatman-Freedman A; Bromberg M; Hershkovitz Y; Sefty H; Kaufman Z; Dichtiar R; Keinan-Boker L
    Emerg Infect Dis; 2022 May; 28(5):948-956. PubMed ID: 35361311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel.
    Yaari R; Kaliner E; Grotto I; Katriel G; Moran-Gilad J; Sofer D; Mendelson E; Miller E; Huppert A; ; Anis E; Kopel E; Manor Y; Mor O; Shulman L; Singer R; Weil M
    BMC Med; 2016 Jun; 14(1):95. PubMed ID: 27334457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a third BNT162b2 vaccine on breakthrough infections in health care workers: a cohort analysis.
    Oster Y; Benenson S; Nir-Paz R; Buda I; Cohen MJ
    Clin Microbiol Infect; 2022 May; 28(5):735.e1-735.e3. PubMed ID: 35143997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
    Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
    BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021.
    Glatman-Freedman A; Hershkovitz Y; Kaufman Z; Dichtiar R; Keinan-Boker L; Bromberg M
    Emerg Infect Dis; 2021 Nov; 27(11):2919-2922. PubMed ID: 34570694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buying Time with COVID-19 Outbreak Response, Israel.
    Leshem E; Afek A; Kreiss Y
    Emerg Infect Dis; 2020 Sep; 26(9):2251-3. PubMed ID: 32620179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign.
    Mattiuzzi C; Lippi G
    Eur J Public Health; 2022 Apr; 32(2):328-330. PubMed ID: 34978571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outbreak of SARS-CoV-2 B.1.617.2 (delta) variant in a nursing home 28 weeks after two doses of mRNA anti-COVID-19 vaccines: evidence of a waning immunity.
    Pierobon A; Zotto AD; Antico A; De Antoni ME; Vianello L; Gennari M; Di Caprio A; Russo F; Brambilla G; Saugo M
    Clin Microbiol Infect; 2022 Apr; 28(4):614.e5-614.e7. PubMed ID: 34958917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.